化合物AZ1
化合物AZ1 性质
| 沸点 | 478.5±40.0 °C(Predicted) |
|---|---|
| 密度 | 1.488±0.06 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | DMSO：≥250mg/mL（592.12mM）；水：< 0.1 mg/mL（不溶） |
| 形态 | 固体 |
| 酸度系数(pKa) | 14.74±0.10(Predicted) |
| 颜色 | 白色至米白色 |
化合物AZ1 用途与合成方法
| Target | Value |
|
USP25
(Cell-free assay) | 0.62 μM |
|
USP28
(Cell-free assay) | 0.7 μM |
USP25/28 inhibitor AZ1 (AZ1; 40 mg/kg; gavage; daily; for 7 days) protects from dextran sulfate sodium (DSS)-induced weight loss and diarrhea and impaired colon shortening.
USP25/28 inhibitor AZ1 (20 mg/kg/day; gavage; 6 times a week in the 1, 3, 6 weeks) treatment significantly reduces tumor numbers in colons. Expression of Wnt-related genes and levels of pSTAT3 are decreased and levels of SOCS3 are increased in tumors. AZ1 gavage does not alleviate DSS-induced colitis in Usp25
-/-
mice or the spontaneous colitis of Il10
-/-
mice.
USP25/28 inhibitor AZ1 (20 mg/kg/day; gavage; every 3 days from 13-20 weeks) significantly inhibits tumorigenesis in the colon and prolonged the survival of AOM/Vil-Cre;Trp53
fl/fl
(VP) mice. AZ1 treatment has minimal effect on tumorigenesis in the USP25-deficient background.
| Animal Model: | 12-week old male Usp25 +/+ and Usp25 -/- mice |
| Dosage: | 40 mg/kg |
| Administration: | Gavage; daily; for 7 days |
| Result: | Protected from dextran sulfate sodium (DSS)-induced weight loss and diarrhea and impaired colon shortening and potentiated the expression of proinflammatory cytokines and antibacterial peptides in colons of Usp25 -/- mice compared to control counterparts. |
化合物AZ1 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-11-08 | HY-117370 | 1 mg | 1090 | ||
| 2024-11-08 | S8904 | 化合物AZ1 | 2165322-94-9 | 5mg | 1270 |
